Literature DB >> 11883825

Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis.

R Padoan1, S Genoni, E Moretti, M Seia, A Giunta, C Corbetta.   

Abstract

UNLABELLED: A study was performed on the delayed diagnosis of cystic fibrosis (CF) in infants who had false-negative results in a neonatal screening programme. The genetic and clinical features of false-negative infants in this screening programme were assessed together with the efficiency of the screening procedure in the Lombardia region. In total, 774,687 newborns were screened using a two-step immunoreactive trypsinogen (IRT) (in the years 1990-1992), IRT/IRT + delF508 (1993-1998) or IRT/IRT + polymerase chain reaction (PCR) and oligonucleotide ligation assay (OLA) protocol (1998-1999). Out of 196 CF children born in the 10 y period 15 were false negative on screening (7.6%) and molecular analysis showed a high variability in the genotypes. The cystic fibrosis transmembrane regulator (CFTR) gene mutations identified were delF508, D1152H, R1066C, R334W, G542X, N1303K, F1052V, A120T, 3849 + 10kbC --> T, 2789 + 5G --> A, 5T-12TG and the novel mutation D110E. In three patients no mutation was identified after denaturing gradient gel electrophoresis of the majority of CFTR gene exons.
CONCLUSION: The clinical phenotypes of CF children diagnosed by their symptoms at different ages were very mild. None of them presented with a severe lung disease. The majority of them did not seem to have been damaged by the delayed diagnosis. The combination of IRT assay plus genotype analysis (1998-1999) appears to be a more reliable method of detecting CF than IRT measurement alone or combined with only the delF508 mutation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11883825     DOI: 10.1080/080352502753458012

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  8 in total

1.  A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis.

Authors:  Janelle Wells; Marjorie Rosenberg; Gary Hoffman; Michael Anstead; Philip M Farrell
Journal:  Pediatrics       Date:  2012-01-30       Impact factor: 7.124

2.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma.

Authors:  Robert R McWilliams; Gloria M Petersen; Kari G Rabe; Leonard M Holtegaard; Pamela J Lynch; Michele D Bishop; W Edward Highsmith
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

3.  Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening.

Authors:  Michael J Rock; Hara Levy; Christina Zaleski; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2011-08-24

4.  Probability of high-risk genetic matching with oocyte and semen donors: complete gene analysis or genotyping test?

Authors:  Marta Molina Romero; Alberto Yoldi Chaure; Miguel Gañán Parra; Purificación Navas Bastida; José Luis Del Pico Sánchez; Ángel Vaquero Argüelles; Paloma de la Fuente Vaquero; Juan Pablo Ramírez López; José Antonio Castilla Alcalá
Journal:  J Assist Reprod Genet       Date:  2022-01-29       Impact factor: 3.412

Review 5.  False negative newborn screen and neonatal cholestasis in a premature child with cystic fibrosis.

Authors:  J F Heidendael; M M Tabbers; I De Vreede
Journal:  Eur J Pediatr       Date:  2013-08-15       Impact factor: 3.183

6.  Newborn Screening Saves Lives but Cannot Replace the Need for Clinical Vigilance.

Authors:  F Neemuchwala; M Taki; E Secord; S Z Nasr
Journal:  Case Rep Pediatr       Date:  2018-07-02

7.  Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients.

Authors:  Lynn Pique; Steve Graham; Michelle Pearl; Martin Kharrazi; Iris Schrijver
Journal:  Genet Med       Date:  2016-05-05       Impact factor: 8.822

8.  Dehydrated patient without clinically evident cause: A case report.

Authors:  Federica Palladino; Maria Cristina Fedele; Marianna Casertano; Laura Liguori; Tiziana Esposito; Stefano Guarino; Emanuele Miraglia Del Giudice; Pierluigi Marzuillo
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.